VBI Vaccines (NASDAQ:VBIV) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

VBIV has been the subject of a number of other reports. Canaccord Genuity initiated coverage on VBI Vaccines in a research report on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price objective for the company. Zacks Investment Research upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. Finally, BMO Capital Markets initiated coverage on VBI Vaccines in a research report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. VBI Vaccines currently has an average rating of “Hold” and an average target price of $10.50.

Shares of VBI Vaccines (VBIV) traded down $0.02 during mid-day trading on Thursday, reaching $4.19. The company had a trading volume of 332,404 shares, compared to its average volume of 162,091. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.03 and a quick ratio of 0.97. VBI Vaccines has a 1 year low of $3.01 and a 1 year high of $6.60.

In other news, CEO Jeff Baxter acquired 15,000 shares of the stock in a transaction that occurred on Tuesday, November 28th. The stock was purchased at an average cost of $4.75 per share, for a total transaction of $71,250.00. Following the completion of the transaction, the chief executive officer now directly owns 135,255 shares in the company, valued at $642,461.25. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Steven Gillis acquired 300,000 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was purchased at an average price of $3.05 per share, with a total value of $915,000.00. Following the completion of the transaction, the director now owns 46,916 shares of the company’s stock, valued at $143,093.80. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 4,070,738 shares of company stock valued at $12,441,251. Corporate insiders own 54.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of VBIV. California State Teachers Retirement System bought a new position in VBI Vaccines during the second quarter worth about $167,000. Schwab Charles Investment Management Inc. bought a new position in VBI Vaccines during the second quarter worth about $187,000. Bank of New York Mellon Corp bought a new position in VBI Vaccines during the second quarter worth about $193,000. Teachers Advisors LLC bought a new position in VBI Vaccines during the second quarter worth about $195,000. Finally, TIAA CREF Investment Management LLC bought a new position in VBI Vaccines during the second quarter worth about $262,000. Hedge funds and other institutional investors own 20.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/07/vbi-vaccines-vbiv-downgraded-by-bidaskclub-to-hold.html.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.